This week officially marks the busiest week of the year for IPO's with twelve different offerings up for grabs.

First up we have BJ's Wholesale (BJ  ) which will likely get the majority of the me media's attention. The Sam's Club and Costco (COST  ) competitor will be looking for $600 million to fuel their growth. They will offer 37.5 million shares at a range of $15 - $17. This would give them a valuation of $2.1 billion.

Domo (DOMO  ) is up next with their $188 million offering. This offering is unique in some respects as the original founder will maintain majority voting control with 86% of the voting rights. The company has had some struggles so the valuation will reflect this. They will offer 9.2 million shares at a range of $19 - $22.

Uxin (UXIN  ) is a Chinese, online autosales marketplace and will be looking for $437 million with their US listing. This would give them a very high valuation of $3.7 billion but they hope investors can look past this and focus on their rapid growth. They will offer 38 million shares at a range of $10.50 - $12.50.

Brightview (BV  ) is a commercial landscaping company in the US and hopes to raise $500 million. Debt is a big focus on this offering as the company has taken quite a lot of debt to fuel their "grow by acquiring" approach. They will offer 21.3 million shares at a range of $22 - $25.

Popular online insurance marketplace, EverQuote (EVER  ) will be looking for $75 million this week. The company has been offering attractive growth numbers going forward but over one third of insiders will be selling on the IPO. They will offer 4.6 million shares at $15 - $17.

Premium beanbag chair and furniture manufacturer LoveSac (LOVE  ) will be looking for $42 million this week. The company has seen rapid growth but competition from larger competitors remains the biggest obstacle. They will offer 3 million shares at a range of $13 - $15.

Dry bulk shipping company GoodBulk (GBLK  ) hopes to raise $140 million this week. Analysts typically do not like this shipping sub sector as it is a highly capital intensive business and this one is no different. Analysts have concerns about growth projections relative to future funding needed. The company will offer 8.5 million shares at $15.50 - $17.50.

There are five biotech names on the books this week. Neon Therapeutics (NTGN  ) which is focused on oncology medications will be looking for $100 million, and Neuronetics (STIM  ) which is a depression device maker will be looking for $75 million are the first two. The third is Translate Bio (TBIO  ) which is a highly complex biotech focused on life threatening diseases. They will be looking for $100 million to complete their phase two trials and hopefully phase three.

The fourth biotech on the books is Tricida (TCDA  ) which is a late stage biotech that will be looking for $175 million. They are very close to a commercial solution for chronic kidney disease. They will offer 10.3 million shares at a range of $16 - $18.

The final biotech name up for grabs this week is Forty Seven (FTSV  ) which also has a focus in the oncology space. They have six products in phase 1 and 2 with it's main medication focused on a specific cancer therapy. 6.7 million shares will be offered at $14 - $16 for this deal.